BethDianeKirkpatrickMD
Infectious Disease • Burlington, VTAssociate Professor, Medicine, University of Vermont College of Medicine
Are you Dr. Kirkpatrick?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
111 Colchester Ave
Fletcher Allen Health Care
Burlington, VT 05401Phone+1 802-847-4594
Summary
- Dr. Beth Kirkpatrick, MD is an infectious disease specialist in Burlington, Vermont. She is currently licensed to practice medicine in Vermont and Maryland. She is affiliated with University of Vermont Medical Center and is an Associate Professor at University of Vermont College of Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 1996 - 1999
University of RochesterResidency, Internal Medicine, 1992 - 1996
Albany Medical CollegeClass of 1992
Certifications & Licensure
VT State Medical License 1999 - 2026
MD State Medical License 1996 - 2000- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Start of enrollment: 2009 Jul 01
- Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection Start of enrollment: 2010 Jan 01
- Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 146 citationsRobust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healt...Beth D. Kirkpatrick, Anna P. Durbin, Kristen K. Pierce, Marya P. Carmolli, Cecilia M. Tibery
The Journal of Infectious Diseases. 2015-09-01 - 182 citationsThe live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge modelBeth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama L. Grier
Science Translational Medicine. 2016-03-16 - 137 citationsThe human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopesDaniela Weiskopf, Michael A. Angelo, Derek J. Bangs, John Sidney, Sinu Paul
Journal of Virology. 2015-01-01
Press Mentions
Colchester's Vernal Biosciences Manufactures the mRNA That’s Revolutionizing MedicineAugust 25th, 2021- Sorely Needed Dengue Vaccine Gets a Boost from Immune ProfilingMay 26th, 2021
- Dengue Immune Function Discovery Could Benefit Much-Needed Vaccine DevelopmentMay 24th, 2021
- Join now to see all
Grant Support
- Vermont Cobre: Project 2: Innate Immune Responses To Cryptosporidium ParvumNational Center For Research Resources2006–2011
- Clinical Trial: Phase I Evaluation Of A Live Attenuated Den4 VaccineNational Center For Research Resources2010
- Campylobacter Jejuni Challenge: Assessment Of Homologous ProtectionNational Center For Research Resources2010
- Campylobactor Jejuni Challenge Model Development: Dose-Ranging StudyNational Center For Research Resources2007–2010
- Gamma-Delta T Cells And CryptosporidiosisNational Institute Of Allergy And Infectious Diseases2004–2008
